Elevated circulating s100a12 associates with vascular disease and worse clinical outcome in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 36, Issue 3, 2016, Pages 269-276

  Isoyama, Naohito ^a,b   Machowska, Anna ^a,c   Qureshi, Abdul Rashid ^a   Yamamoto, Tae ^d   Anderstam, Björn ^a   Heimburger, Olof ^a   Barany, Peter ^a   Stenvinkel, Peter ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b YAMAGUCHI UNIVERSITY   (Japan)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products (AGE); All cause mortality; Cardiovascular disease; End stage renal disease; Inflammation; Receptor of AGE (RAGE); Soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN C; INTERLEUKIN 6; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR DISEASE; BLOOD; CASE CONTROL STUDY; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; VASCULAR DISEASES;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; S100A12 PROTEIN; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84970021643     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2014.00121     Document Type: Article

References (29)

1. Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr 2012; 22(1):120-7.
2. Stenvinkel P, Carrero J, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3(2):505-21.
3. Leurs P, Lindholm B. The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease. Arch Med Res 2013; 44(8):601-10.
4. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17(6):436-43.
5. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62(6):2116-21.
6. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29(1):18-24.
7. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106(22):2827-35.
8. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25(12):2587-93.
9. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91(11):4628-34.
10. Zakiyanov O, Kalousova M, Kriha V, Zima T, Tesar˘ V. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press Res 2011; 34(6):457-64.
11. Kalousová M, Kubena AA, Benáková H, Dusilová-Sulková S, Tesar V, Zima T. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: a prospective observational cohort study. Clin Biochem 2012; 45(7-8):556-60.
12. Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008;81(2):196-201.
13. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155(1):75-81.
14. Wang YN, Sun Y, Wang Y, Jia YL. Serum S100A12 and progression of coronary artery calcification over 4 years in hemodialysis patients. Am J Nephrol 2015;42(1):4-13.
15. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220(1):208-14.
16. Uchiyama-Tanaka Y, Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008; 12(1):28-32.
17. Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 2015; 30(1):84-91.
18. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5(12):2213-9.
19. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974; 32(1):77-97.
20. Kyle UG, Schutz Y, Dupertuis YM, Pichard C. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition 2003; 19(7-8):597-604
21. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53(3):773-82.
22. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17(6):1085-92.
23. Xu H, Watanabe M, Qureshi A, Heimbürger O, Bárány P, Anderstam B, et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 2014; 35(2):206-15.
24. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
25. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21(9):2549-55.
26. Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Wieslander A, Haug U, et al. Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure. Perit Dial Int 2010; 30(1):35-40.
27. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59(1):249-55.
28. Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77(3):225-31.
29. Bakkaloglu SA, Saygili A, Sever L, Noyan A, Akman S, Ekim M, et al. Assessment of cardiovascular risk in paediatric peritoneal dialysis patients: a Turkish Pediatric Peritoneal Dialysis Study Group (TUPEPD) report. Nephrol Dial Transplant 2009; 24(11):3525-32.